NO
Last reporting period 30 Jun, 2024
Updated 18 Sep, 2024
Last price
—
Market cap $B
64.868
Exchange
OOTC - OTC
62.7 B
Last period Cash and equivalents ,DKK
333%
Cash and equivalents has increased in 5 years
What is Cash and equivalents ?
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
See also Novo Nordisk
Company Analysis
NONOF valuation, rating, competitors, insights and company profile
Eyestock Rating
NONOF financial analysis by Eyestock methodology
Valuation
NONOF valuation using historical relative method
Statements
NONOF Income Statements, Balance Sheet and Cash Flow Statements
Dividends
NONOF dividend yield and annual dividend
Cash is the amount of free cash on the company's accounts, as well as short-term liquid investments.
Novo Nordisk`s Cash and equivalents for the period ended 2024-06-30 are 62.7 B DKK
